|
CA2830349C
(en)
|
2011-03-17 |
2019-07-16 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
US10322949B2
(en)
|
2012-03-15 |
2019-06-18 |
Flodesign Sonics, Inc. |
Transducer and reflector configurations for an acoustophoretic device
|
|
US9950282B2
(en)
|
2012-03-15 |
2018-04-24 |
Flodesign Sonics, Inc. |
Electronic configuration and control for acoustic standing wave generation
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10967298B2
(en)
|
2012-03-15 |
2021-04-06 |
Flodesign Sonics, Inc. |
Driver and control for variable impedence load
|
|
US9745548B2
(en)
|
2012-03-15 |
2017-08-29 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9458450B2
(en)
|
2012-03-15 |
2016-10-04 |
Flodesign Sonics, Inc. |
Acoustophoretic separation technology using multi-dimensional standing waves
|
|
US10689609B2
(en)
|
2012-03-15 |
2020-06-23 |
Flodesign Sonics, Inc. |
Acoustic bioreactor processes
|
|
US9752113B2
(en)
|
2012-03-15 |
2017-09-05 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US10737953B2
(en)
|
2012-04-20 |
2020-08-11 |
Flodesign Sonics, Inc. |
Acoustophoretic method for use in bioreactors
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
US9745569B2
(en)
|
2013-09-13 |
2017-08-29 |
Flodesign Sonics, Inc. |
System for generating high concentration factors for low cell density suspensions
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US20170044268A1
(en)
*
|
2013-12-23 |
2017-02-16 |
OncoMed Pharmaceuticals |
Immunotherapy with Binding Agents
|
|
US20160376374A1
(en)
*
|
2014-01-02 |
2016-12-29 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
|
|
CA2935960C
(en)
|
2014-01-08 |
2023-01-10 |
Bart Lipkens |
Acoustophoresis device with dual acoustophoretic chamber
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
FI3888674T3
(fi)
|
2014-04-07 |
2024-07-02 |
Novartis Ag |
Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
|
|
AP2016009504A0
(en)
*
|
2014-04-27 |
2016-10-31 |
Ccam Biotherapeutics Ltd |
Humanized antibodies against ceacam1
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
US9744483B2
(en)
|
2014-07-02 |
2017-08-29 |
Flodesign Sonics, Inc. |
Large scale acoustic separation device
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
EA201790737A1
(ru)
|
2014-10-03 |
2017-08-31 |
Новартис Аг |
Комбинированная терапия
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
WO2016120331A1
(de)
|
2015-01-28 |
2016-08-04 |
Karl Sebastian Lang |
Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3253419A1
(en)
|
2015-02-02 |
2017-12-13 |
The University of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11021699B2
(en)
|
2015-04-29 |
2021-06-01 |
FioDesign Sonics, Inc. |
Separation using angled acoustic waves
|
|
CA3022547A1
(en)
|
2015-05-12 |
2016-11-17 |
Syntimmune, Inc. |
Humanized affinity matured anti-fcrn antibodies
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
US20180214553A1
(en)
*
|
2015-07-24 |
2018-08-02 |
Oncotracker, Inc. |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
US11474085B2
(en)
|
2015-07-28 |
2022-10-18 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
US11459540B2
(en)
|
2015-07-28 |
2022-10-04 |
Flodesign Sonics, Inc. |
Expanded bed affinity selection
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
KR20180041229A
(ko)
*
|
2015-08-25 |
2018-04-23 |
유에이비 리서치 파운데이션 |
줄기 세포 이식을 위한 방법
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
TWI730013B
(zh)
*
|
2015-11-20 |
2021-06-11 |
生華生物科技股份有限公司 |
用於治療癌症的四環喹諾酮類似物組合療法
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
US11433136B2
(en)
|
2015-12-18 |
2022-09-06 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11085035B2
(en)
|
2016-05-03 |
2021-08-10 |
Flodesign Sonics, Inc. |
Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
|
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
|
WO2018019380A1
(de)
*
|
2016-07-28 |
2018-02-01 |
Universität Duisburg-Essen |
Immunstimulatorische anti-ceacam1-antikörper
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110494543A
(zh)
|
2016-10-19 |
2019-11-22 |
弗洛设计声能学公司 |
通过声学的亲和细胞提取
|
|
MA46961A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Procédés de modulation de lymphocytes t modifiés par car
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
KR102019913B1
(ko)
*
|
2017-03-24 |
2019-09-09 |
재단법인 목암생명과학연구소 |
항-ceacam1 항체 및 이의 용도
|
|
TWI682940B
(zh)
*
|
2017-03-24 |
2020-01-21 |
財團法人牧岩生命科學研究所 |
抗ceacam1抗體及其用途
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
AU2018291032A1
(en)
|
2017-06-29 |
2020-01-16 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
KR20220066413A
(ko)
|
2017-12-14 |
2022-05-24 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
|
CA3120118A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
JP2022513729A
(ja)
*
|
2018-12-07 |
2022-02-09 |
ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド |
ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体
|
|
MX2021009087A
(es)
|
2019-01-29 |
2021-09-08 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
|
|
JP2022550067A
(ja)
*
|
2019-09-27 |
2022-11-30 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｅａｃａｍ抗体及びその使用
|
|
MX2022005308A
(es)
*
|
2019-11-07 |
2022-05-26 |
Green Cross Corp |
Epitopo esterico de ceacam1, y anticuerpo anti-ceacam1, o fragmento del mismo, que se une especificamente al mismo.
|
|
CN114945382A
(zh)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
Cd19和cd22嵌合抗原受体及其用途
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
AU2021273744A1
(en)
|
2020-05-19 |
2022-12-08 |
Pharmacosmos Holding A/S |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
CN116437913A
(zh)
|
2020-09-23 |
2023-07-14 |
艾其林医药公司 |
用于治疗补体介导的病症的药物化合物
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
JP2025508963A
(ja)
*
|
2022-03-03 |
2025-04-10 |
ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイティド |
ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体及びその使用方法
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
EP4633664A2
(en)
|
2022-12-13 |
2025-10-22 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024165403A1
(en)
|
2023-02-06 |
2024-08-15 |
Philogen S.P.A. |
Anti-cea antibodies
|